News Conference News ESC 2025 ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD L.A. McKeown September 09, 2025
News Opinion Editor's Corner ESC 2025 What’s Going to Be Hot at ESC Congress 2025? Michael O'Riordan August 25, 2025
News Conference News ESC 2024 Trial Challenges Continuation of Oral Anticoagulants During TAVI Todd Neale August 31, 2024
Presentation ESC 2024 Continuation versus Interruption of Oral Anticoagulation during TAVI Presenter: Dirk-Jan van Ginkel August 31, 2024
News Conference News ESC 2022 CV Care Around Noncardiac Surgery: New ESC Guidelines Michael O'Riordan September 07, 2022
News Conference News ESC 2022 INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF Michael O'Riordan August 28, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Conference News ESC 2021 ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting Todd Neale August 28, 2021
News Conference News ESC 2019 Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints Todd Neale September 11, 2019
News Conference News ESC 2019 LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17 Todd Neale September 10, 2019
News Conference News ESC 2019 ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More Shelley Wood August 22, 2019
News Conference News ESC 2018 Atrial Fibrillation, Oral Anticoagulation Linked With Mortality After TAVR: FRANCE-TAVI Michael O'Riordan August 25, 2018
News Conference News ESC 2018 ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More Shelley Wood August 20, 2018
News Opinion Editor's Corner ESC 2017 ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On Shelley Wood August 18, 2017